1. Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL;
2. Université de Paris, INSERM UMR 976, Saint Louis Research Institute, Paris, France;
3. French National Reference Center for Histiocytoses, Department of Pulmonology, Saint-Louis Teaching Hospital, Assistance Publique-Hôpiaux de Paris, Paris, France;
4. Divison of Hematology, and
5. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;
6. Division of Pathology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH;
7. Division of Pulmonary and Critical Care Medicine, and
8. Department of Radiology, Mayo Clinic, Rochester, MN;
9. Department of Internal Medicine, and
10. Department of Immunology, Erasmus University Medical Center, Rotterdam. The Netherlands;
11. Division of Pediatric Hematology-Oncology, University of California, San Francisco, San Francisco, CA;
12. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;
13. LCH Adult Clinic, and
14. Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece;
15. 1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Greece;
16. Service de médecine interne 2, Centre de Référence des Histiocytoses, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France;
17. Newcastle University and Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, United Kingdom;
18. Texas Children’s Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX;
19. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY; and
20. Internal Medicine I (Hemostasis, Hematology and Stem, Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria